News

Kenai Therapeutics has completed patient enrollment in a small, early clinical trial testing the safety and effectiveness of RNDP-001, its direct-to-the-brain cell therapy for treating an underlying cause of Parkinson’s disease. The Phase 1b/2a REPLACE trial (NCT07106021), now underway at three sites in the U.S., has recruited…

National Football League players had nearly four times the expected mortality rate from neurodegenerative diseases, including Parkinson’s disease, despite having lower overall mortality than the general population, a large study found. Researchers at Mass General Brigham, Boston University, and the Concussion & CTE Foundation conducted the study, which included nearly…

Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial. This brings the total number of adults with Parkinson’s who received sasineprocel in the…

Gut bacteria that produce vitamin B6 may help nerve cells in the brain produce dopamine, a chemical involved in motor control that is missing in Parkinson’s disease, according to an animal study. The research in worms and mice adds to a growing understanding of how the gut-brain axis is…

The first meeting of the National Parkinson’s Project Advisory Council, held on June 29, ended with a commitment to deliver a first report by summer 2027, while acknowledging that more clarity is needed on the federal funding required for Parkinson’s disease research and care. The National Parkinson’s Project…

Many people with advanced Parkinson’s disease may actually not have widespread accumulation of toxic protein clumps known as Lewy bodies, which have long been thought to accompany the neurological condition in its later stages, according to a new study from U.S. researchers. The scientists found that most…

A growing body of research suggests that the gut microbiome — the community of bacteria and other microscopic organisms that live in the human digestive tract — may play key roles in the development and progression of Parkinson’s disease. Data suggest that it may be possible to develop Parkinson’s…

The U.S. Food and Drug Administration (FDA) has given Gain Therapeutics a green light to launch a clinical trial — to run across three continents — testing GT-02287, an oral therapy designed to prevent the formation of toxic protein clumps in Parkinson’s disease. The agency clearance follows positive early…

Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these participants received a new, commercial-ready formulation of the cell therapy designed to make future manufacturing and treatment…

A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and carbidopa sold in the U.S. under the brand name Crexont — for people with Parkinson’s disease in the European Union who experience motor fluctuations despite treatment. The EMA’s…